Technical Analysis for CNTB - Connect Biopharma Holdings Limited

Grade Last Price % Change Price Change
C 17.27 -0.17% -0.03
CNTB closed down 0.17 percent on Friday, April 16, 2021, on 22 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical CNTB trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Inside Day Range Contraction -0.17%
NR7 Range Contraction 1.29%
NR7-2 Range Contraction 1.29%
Inside Day Range Contraction 1.29%
Hot IPO Pullback Bullish Swing Setup 1.59%
NR7 Range Contraction 1.59%
Inside Day Range Contraction 1.59%
Hot IPO Pullback Bullish Swing Setup 5.30%
Older End-of-Day Signals for CNTB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
Fell Below 10 DMA 1 day ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Connect Biopharma Holdings Limited Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


Classification

Sector: Other
Industry: Other
Keywords: Biopharmaceutical Biology Immunology Immune System Immunotherapy Inflammation Asthma Atopic Dermatitis Animal Physiology Chronic Rhinosinusitis Skin Inflammation Human Physiology Nasal Polyps

Is CNTB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.2899
52 Week Low 15.2909
Average Volume 214,674
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 17.14
10-Day Moving Average 17.19
Average True Range 1.66
ADX 0.0
+DI 15.62
-DI 11.27
Chandelier Exit (Long, 3 ATRs ) 18.32
Chandelier Exit (Short, 3 ATRs ) 20.26
Upper Bollinger Band 18.77
Lower Bollinger Band 15.52
Percent B (%b) 0.54
BandWidth 18.98
MACD Line 0.01
MACD Signal Line -0.02
MACD Histogram 0.0303
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.58
Resistance 3 (R3) 18.47 17.94 18.36
Resistance 2 (R2) 17.94 17.60 17.99 18.28
Resistance 1 (R1) 17.60 17.40 17.77 17.71 18.21
Pivot Point 17.07 17.07 17.15 17.12 17.07
Support 1 (S1) 16.73 16.73 16.90 16.84 16.33
Support 2 (S2) 16.20 16.53 16.25 16.26
Support 3 (S3) 15.86 16.20 16.18
Support 4 (S4) 15.97